The effects of the combination therapy of DPP-4 inhibitor alogliptin and alfa-glucosidase inhibitor on markers of inflammation and oxidative stress - comparison between Acarbose and Voglibose

The effects of the combination therapy of DPP-4 inhibitor alogliptin and alfa-glucosidase inhibitor on markers of inflammation and oxidative stress - comparison between Acarbose and Voglibose - Combination therapy of DPP-4 inhibitor and alfa-glucosidase inhibitor

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007714

Enrollment

Registered

2012-05-01

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

Administration of Acarbose Administration of Voglibose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The patients with type 2 diabetes mellitus who gave written informed consent to take part in this clinical study 2. The patients who has been taking DPP-4 inhibitor for more than 3 months and whose HbA1c (JDS) level is 6.5 % or higher.

Exclusion criteria

Exclusion criteria: 1. type 1 diabetes mellitus 2. diabetes ketoacidosis, coma, or pre-coma 3. patients with severe infection, severe trauma, or in perioperative period 4. patients who have allergy to the medicine used in this trial 5.(possible) pregnant women

Design outcomes

Primary

Measure	Time frame
Oxitative stress markaer (urinary 8-OHdG, oxidative LDL) Inflammatory marker (TNF-alfa, hs-CRP)	—

Secondary

Measure	Time frame
Postchallenge plasma glucose concentration	—

Countries

Japan

Contacts

Public ContactMasami Tanaka

School of Medicine, Keio University Department of Internal Medicine

tana176k@a7.keio.jp03-5363-3797

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026